GSE130396 neratinib 0 v 6 human dn (Gene Set)

Analyze

Playbook Workflow Builder
Playbook Workflow Builder: Gene Set Enrichment

Perform Gene Set Enrichment with this gene set against Common Fund program's gene sets, identifying significant overlaps using a pre-built PWB workflow. Run the workflow with GSE130396_neratinib_0_v_6_human_dn.

GeneSetCart
GeneSetCart

GeneSetCart helps you to fetch gene sets from various data sources, augment, combine with set operations, visualize and analyze these gene sets in a single session. Start a new session with GSE130396_neratinib_0_v_6_human_dn.

CFDE-GSE
CFDE Gene Set Enrichment (GSE)

CFDE-GSE illuminates connections between the input gene set and various CF gene sets that overlap with the queried gene set. Query CFDE-GSE with GSE130396_neratinib_0_v_6_human_dn.

Playbook Workflow Builder
Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with GSE130396_neratinib_0_v_6_human_dn.

Results found

Linked to

 

Label

Description

 

Gene

CDH13 antisense RNA 2

Gene

MSANTD2 antisense RNA 1

Gene

sialic acid binding Ig like lectin 17, pseudogene

Gene

long intergenic non-protein coding RNA 2241

Gene

HUWE1 associated protein modifying stress responses 2

Gene

uncharacterized LOC124901789

Gene

RSG2 antisense RNA 1

Gene

uncharacterized LOC105373352

Gene

uncharacterized LOC105371993

Gene

VIRMA divergent transcript

  • Gene

    CDH13 antisense RNA 2


  • Gene

    MSANTD2 antisense RNA 1


  • Gene

    sialic acid binding Ig like lectin 17, pseudogene


  • Gene

    long intergenic non-protein coding RNA 2241


  • Gene

    HUWE1 associated protein modifying stress responses 2


  • Gene

    uncharacterized LOC124901789


  • Gene

    RSG2 antisense RNA 1


  • Gene

    uncharacterized LOC105373352


  • Gene

    uncharacterized LOC105371993


  • Gene

    VIRMA divergent transcript

  • DISPLAY PER PAGE
    This repository is under review for potential modification in compliance with Administration directives.